within Pharmacolibrary.Drugs.ATC.C;

model C01DX19
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00015,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.000195,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00016,
    k12             = 7,
    k21             = 7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01DX19</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Nesiritide is a recombinant form of human B-type natriuretic peptide (BNP), used as a vasodilator for the treatment of acutely decompensated heart failure. It has been used in hospital settings for short-term intravenous therapy in patients with heart failure who have dyspnea at rest or with minimal activity. The drug is not commonly used today, as newer therapies have supplanted its use, and concerns have been raised about safety and efficacy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult heart failure patients following intravenous infusion.</p><h4>References</h4><ol><li><p>Täubel, J, et al., &amp; Thum, T (2021). Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. <i>European heart journal</i> 42(2) 178–188. DOI:<a href=&quot;https://doi.org/10.1093/eurheartj/ehaa898&quot;>10.1093/eurheartj/ehaa898</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33245749/&quot;>https://pubmed.ncbi.nlm.nih.gov/33245749</a></p></li><li><p>Keating, GM, &amp; Goa, KL (2003). Nesiritide: a review of its use in acute decompensated heart failure. <i>Drugs</i> 63(1) 47–70. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200363010-00004&quot;>10.2165/00003495-200363010-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12487622/&quot;>https://pubmed.ncbi.nlm.nih.gov/12487622</a></p></li><li><p>Maisel, AS (2003). Nesiritide: a new therapy for the treatment of heart failure. <i>Cardiovascular toxicology</i> 3(1) 37–42. DOI:<a href=&quot;https://doi.org/10.1385/ct:3:1:37&quot;>10.1385/ct:3:1:37</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12668889/&quot;>https://pubmed.ncbi.nlm.nih.gov/12668889</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01DX19;
